Abstract
It is well accepted that the Bcr-Abl oncoprotein encoded by the Philadelphia chromosome is responsible for causing chronic myelogenous leukemia (CML). We have previously demonstrated that expression of Bcr interferes with the oncogenic effects of Bcr-Abl. To examine the effects of increased Bcr expression on Bcr-Abl oncogenic effects in a more physiological system, we tested the leukemogenic potential of a clone of K562 cells (K6 K562) containing an inducible BCR gene in NOD/scid mice. In this clone, the BCR gene was placed under the control of a tetracycline (Tet) repression system with a cytomegalovirus (CMV) promoter. Induction of exogenous Bcr protein by removal of Tet from the culture medium caused a dramatic increase in Bcr serine kinase activity, yielding predominantly phosphoserine Bcr, despite the presence of Bcr-Abl in the kinase reaction mixture. Prior to induction, the endogenous Bcr was predominantly in the phosphotyrosine form because of phosphorylation by Bcr-Abl, which we previously have shown suppresses Bcr serine/threonine kinase activity. Injection of K6 K562 cells into NOD/scid mice under conditions where BCR expression was suppressed resulted in death or terminal illness in 100% of the mice within 35 days after injection. These mice had a severe wasting syndrome characterized by atrophy of bone marrow hematopoiesis, and/or neoplasia of liver, bone marrow and spleen. Neoplastic spleens from these mice usually contained b3a2 Bcr-Abl transcripts. In contrast, induction of BCR expression at the time of injection allowed 80% survival; these healthy mice had no detectable microscopic lesions in blood forming organs. This difference in survival was significant with P<0.0001. Of interest, mice that were fed Tet for 19 days to initiate the disease syndrome and then released from the BCR transcriptional block had a significantly better survival pattern than mice exposed to Tet throughout the entire period. Moreover, 30% of these mice (three mice) survived through day 50. We conclude from these findings that BCR gene expression strongly inhibits the oncogenic effects of Bcr-Abl in NOD/scid mice, yielding healthy mice in most cases.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Arlinghaus RB . 1998 Crit. Rev. Oncogenesis 9: 1–18
Braselman S, McCormick F . 1995 EMBO J. 14: 4839–4848
Bonnet D, Dick J . 1997 Nat. Med. 3: 730–737
Campbell M, Li W, Arlinghaus RB . 1990 Oncogene 5: 773–776
Dazzi F, Capelli D, Hasserjian R, Cotter F, Corbo M, Poletti A, Chinswangwatanakul W, Goldman JM, Gordon MY . 1998 Blood 92: 1390–1396
Dazzi F, Gordon M, Chinswangwatanakul W, Cotter F, Evans M, Hasserjian R, Grand F, Goldman JM . 1997 Blood 90: Suppl. 1 8
Daley GQ, van Etten RA, Baltimore D . 1990 Science 247: 824–830
Gross AW, Zhang X, Ren R . 1999 Mol. Cell. Biol. 19: 6918–6928
Hawk N, Liu J, Wu Y, Arlinghaus RB . 1997 Blood 90: Suppl. 2 277b
Hu A-ZX, Ji W, Zhou Y, Logothetis C, Xu H-J . 1997 Cancer Res. 57: 3339–3343
Heisterkamp N, Jenster G, ten Hoeve H, Zovich D, Pattengale PK, Groffen J . 1990 Nature 334: 251–258
Huettner D, Zhang P, Van Etten RA, Tenen DG . 2000 Nature Genet. 24: 57–60
Lewis ID, McDiarmid LA, Samels LM, To LB, Hughes TP . 1998 Blood 91: 630–640
Li W, Draezen O, Kloetzer WS, Gale RP, Arlinghaus RB . 1989 Oncogene 4: 127–138
Lin F, van Rhee F, Goldman JM, Cross NCP . 1996 Blood 87: 4473–4478
Liu J, Campbell M, Guo JQ, Lu D, Xian YM, Andersson BS, Arlinghaus RB . 1993 Oncogene 8: 101–109
Liu J, Wu Y, Arlinghaus RB . 1996a Cancer Res. 56: 5120–5124
Liu J, Wu Y, Lu D, Haataja L, Heisterkamp N, Groffen J, Arlinghaus RB . 1996 Mol. Cell. Biol. 16: 998–1005
Lozzio CB, Lozzio BB . 1975 Blood 45: 321–334
Ma G, Lu D, Wu Y, Liu J, Arlinghaus RB . 1997 Oncogene 14: 2367–2372
Maru ON, Witte ON . 1991 Cell 67: 459–468
McWhirter JR, Galasso DL, Wang JYJ . 1993 Mol. Cell. Biol. 13: 7587–7595
Muller AJ, Young JC, Pendergast AM, Pondel M, Landau RN, Littman DR, Witte ON . 1991 Mol. Cell. Biol. 11: 1785–1792
Pendergast AM, Muller AJ, Havlik MH, Maru Y, Witte ON . 1991 Cell 66: 161–171
Wu Y, Ma G, Lu D, Lin F, Xu H-J, Liu J, Arlinghaus RB . 1999 Oncogene 18: 4416–4424
Wu Y, Liu J, Arlinghaus RB . 1998 Oncogene 16: 141–146
Acknowledgements
These studies were supported by grant CA16672 and CA49639 from NIH. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of NIH.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lin, F., Monaco, G., Sun, T. et al. BCR gene expression blocks Bcr-Abl induced pathogenicity in a mouse model. Oncogene 20, 1873–1881 (2001). https://doi.org/10.1038/sj.onc.1204409
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204409
Keywords
This article is cited by
-
MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia
Leukemia (2023)
-
Transcription and signalling pathways involved in BCR–ABL-mediated misregulation of 24p3 and 24p3R
The EMBO Journal (2009)
-
Kinase domain mutants of Bcr enhance Bcr-Abl oncogenic effects
Oncogene (2008)
-
Lipocalin 2 is required for BCR-ABL-induced tumorigenesis
Oncogene (2008)
-
Bcr is a negative regulator of the Wnt signalling pathway
EMBO reports (2005)